Genezen Announces Strategic Process Development and Manufacturing Partnership Agreement with Seattle Children’s Research Institute for X-linked Agammaglobulinemia (XLA) Cell Therapy Program

Seattle Children’s Research Institute, the research division of Seattle Children’s Hospital and renowned global leader in pediatric research, and Genezen, a leading gene and cell therapy contract development and manufacturing organization, have unveiled a strategic manufacturing partnership for Seattle Children’s Research Institute’s X-linked agammaglobulinemia program.

Scroll to Top